Brain+ A/S
Quotes
Share:
Subscribe:
news.cision.com
/
Brain+ A/S
/
Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+’ first commercial dementia product, CST
/
1 B EN RGB
1 B EN RGB
Fri, Jun 24, 2022 08:30 CET
new
Low resolution
Medium resolution
Original resolution
Subscribe
Related Releases
New UK Labour government will focus on healthtech and dementia treatment as part of UK healthcare reform
Fri, Jul 12, 2024 10:31 CET
The CST Assistant v2.0 for Cognitive Stimulation Therapy (CST) now released in Denmark
Tue, Jul 09, 2024 10:18 CET
Directed issue of units to guarantors and registration of shares from both the rights issue and the directed issue
Fri, Jul 05, 2024 13:34 CET